Market Overview

Mirati Therapeutics Sitravatinib Data, Explained

Share:
Mirati Therapeutics Sitravatinib Data, Explained
Related MRTX
Benzinga's Top Upgrades, Downgrades For December 21, 2017
Lightning Round: Jim Cramer Gives His Opinion On Lowe's Companies, Blackstone And More
Healthcare - Top 5 Gainers / Losers as of 11:00 am (1/18/2018) (Seeking Alpha)

Mirati Therapeutics, Inc. (NASDAQ: MRTX) shares are skyrocketing Friday in reaction to its announcement of positive preliminary data from two ongoing clinical trials of its non-small cell lung cancer, or NSCLC, candidate sitravatinib.

The company said the data will be presented at the IASLC 2017 Chicago Multidisciplinary Symposium in Thoracic Oncology on Friday.

At time of writing, shares of Mirati were up 120 percent to $10.40.

See Also: Attention Biotech Investors: September Ushers In Another Slew Of PDUFA Catalysts

Leerink analysts Michael Schmidt, Varun Kumar and Jonathan Chang indicated that a new anecdotal case report of a single agent response, as well as clinical activity in combination with Bristol-Myers Squibb Co (NYSE: BMY)‘s Opdivo in difficult to treat NSCLC patients not responding anymore to anti-PDI inhibitors will also be presented.

Leerink sees these early updates as positive news for Mirati. Additionally, the firm said this could potentially have a beneficial effect on the accrual of ongoing single agent cohorts, as well as development prospects in combination with Opdivo.

"Mirati's pipeline agents hold the promise to address compelling niche markets in cancer patients with rare genetic alterations," the analysts said in a note.

However, Leerink noted that trial enrollment has been slow and differentiation from other agents approved or in development is difficult to determine.

The firm views the first Opdivo combo results as an important positive data point, while it looks forward to additional results in a larger patient cohort.

As such, Leerink raised its price target by $2 to $9 to include probability-adjusted value for the Opdivo combination opportunity for sitravatinib in non-squamous NSCLC. The firm has a Market Perform rating on shares.

Latest Ratings for MRTX

DateFirmActionFromTo
Dec 2017Cowen & Co.Initiates Coverage OnOutperform
Nov 2017H.C. WainwrightMaintainsBuy
Nov 2017Leerink SwannUpgradesMarket PerformOutperform

View More Analyst Ratings for MRTX
View the Latest Analyst Ratings

Posted-In: Jonathan Chang LeerinkAnalyst Color Health Care Price Target Top Stories Analyst Ratings General Best of Benzinga

 

Related Articles (BMY + MRTX)

View Comments and Join the Discussion!